Publications by authors named "E Serra-Baldrich"
Defining the Care Pathway in Patients with Psoriasis and Atopic Dermatitis.
Patient Prefer Adherence
November 2024
Article Synopsis
- - The study explores the clinical pathway for psoriasis and atopic dermatitis (AD) to enhance patient care by identifying needs and experiences at a tertiary hospital.
- - A mixed-method approach, including literature review, questionnaires for healthcare professionals, and focus groups with HCPs and patients, revealed significant pre-diagnosis delays and challenges in accessing timely treatment.
- - The findings suggest interventions to reduce wait times and improve treatment effectiveness, emphasizing the need for better coordination and resources in patient management for psoriasis and AD.
Background: Abrocitinib, a selective JAK 1 inhibitor, was recently approved in Europe. Despite its approval, real-world data on its efficacy and safety in treating moderate-to-severe atopic dermatitis (AD) remains limited.
Objectives: This study aimed to evaluate the short-term effectiveness and safety of abrocitinib in a real-life setting for patients with moderate-to-severe AD.
Article Synopsis
- Patch test outcomes can be affected by age, but there are mixed findings on how age impacts these results.
- The study involved over 13,000 patients and revealed that middle-aged adults (31-65 years) had the highest rates of positive skin sensitisation results, particularly for certain substances like nickel and potassium dichromate.
- Overall, while age does influence some patch test results, most allergens showed consistent reactivity across ages, underscoring the importance of standard testing regardless of age.
Article Synopsis
- Chronic nodular prurigo (CNP) is a long-lasting skin condition causing intense itching and the formation of nodular lesions.
- The study aimed to develop a consensus among experts for a clinical diagnosis of CNP through literature review and an organized diagnostic algorithm.
- The algorithm includes three main steps: identifying potential CNP cases, diagnosing and assessing the condition, and categorizing CNP based on underlying factors, promoting a multidisciplinary treatment approach.
Background: Reports of allergic contact dermatitis (ACD) to phytonadione epoxide (PE) in cosmetics suggest that PE is as powerful a sensitiser as its parent compound phytonadione.
Objective: To evaluate a case series of ACD to PE in Spain.
Methods: We reviewed the records of 20 patients with ACD to cosmetics containing PE diagnosed across Spain between January 2019 and June 2023.